全文获取类型
收费全文 | 3380篇 |
免费 | 1058篇 |
国内免费 | 20篇 |
专业分类
耳鼻咽喉 | 167篇 |
儿科学 | 58篇 |
妇产科学 | 85篇 |
基础医学 | 11篇 |
口腔科学 | 162篇 |
临床医学 | 1075篇 |
内科学 | 773篇 |
皮肤病学 | 96篇 |
神经病学 | 148篇 |
特种医学 | 182篇 |
外科学 | 704篇 |
综合类 | 6篇 |
现状与发展 | 1篇 |
预防医学 | 436篇 |
眼科学 | 49篇 |
药学 | 25篇 |
肿瘤学 | 480篇 |
出版年
2024年 | 34篇 |
2023年 | 243篇 |
2022年 | 60篇 |
2021年 | 132篇 |
2020年 | 242篇 |
2019年 | 74篇 |
2018年 | 243篇 |
2017年 | 236篇 |
2016年 | 275篇 |
2015年 | 281篇 |
2014年 | 378篇 |
2013年 | 372篇 |
2012年 | 148篇 |
2011年 | 148篇 |
2010年 | 210篇 |
2009年 | 336篇 |
2008年 | 133篇 |
2007年 | 120篇 |
2006年 | 139篇 |
2005年 | 97篇 |
2004年 | 87篇 |
2003年 | 57篇 |
2002年 | 37篇 |
2001年 | 46篇 |
2000年 | 46篇 |
1999年 | 53篇 |
1998年 | 46篇 |
1997年 | 47篇 |
1996年 | 31篇 |
1995年 | 31篇 |
1994年 | 17篇 |
1993年 | 7篇 |
1992年 | 14篇 |
1991年 | 4篇 |
1990年 | 7篇 |
1989年 | 6篇 |
1988年 | 6篇 |
1987年 | 2篇 |
1986年 | 3篇 |
1985年 | 1篇 |
1984年 | 1篇 |
1981年 | 2篇 |
1980年 | 1篇 |
1977年 | 3篇 |
1972年 | 1篇 |
1954年 | 1篇 |
排序方式: 共有4458条查询结果,搜索用时 15 毫秒
21.
22.
23.
24.
25.
26.
27.
Dr. Mary S. Brady MD Carol F. Garfein MBA Jeanne A. Petrek MD Murray F. Brennan MD 《Annals of surgical oncology》1994,1(1):66-72
Background: Many patients treated for breast cancer with radiotherapy will survive their disease and be at risk for treatment-related sarcoma for many years.
Methods: In order to identify patients with post-treatment sarcoma and define this disease, we examined the records of 99 patients treated for sarcoma with a history of antecedent breast carcinoma. Of these patients, 51 were felt to have a sarcoma unrelated to breast cancer treatment and 48 were felt to have a treatment-related sarcoma (secondary to lymphedema and/or radiation).
Results: Lymphangiosarcoma of the extremity was the most common histologic subtype of post-treatment sarcoma, accounting for 22 of 48 cases (46%). Twenty-six patients (54%) developed nonlymphangiosarcoma post-treatment sarcoma; all of these were radiation-associated sarcomas. The median latency interval between the diagnosis of breast cancer and the development of sarcoma was 11 years (range 4–44) and was not different between the two groups. However, patients with nonlymphangiosarcoma were significantly younger when diagnosed with breast cancer than were those with lymphangiosarcoma of the extremity (median 43 vs. 51 years, p<0.001). The survival of all 48 patients was poor: 5-year survival was 29%. Five-year survival of patients with other types of post-treatment sarcoma was just as poor as those with lymphangiosarcoma of the extremity (30% vs. 28%, p=0.98).
Conclusions: Patients who develop sarcoma after treatment for breast cancer have a poor prognosis whether it occurs as Stewart-Treves syndrome or other types of post-treatment sarcoma. Younger patients may be at higher risk than are older patients for the development of nonlymphangiosarcoma post-treatment sarcoma.Presented at the 46th Annual Cancer Symposium of the Society of Surgical Oncology, Los Angeles, March 18–21, 1993. 相似文献
28.
29.
As the nursing shortage escalates, nurse managers will continue to grapple with how to retain their most valuable asset—the talented staff they are charged to lead. Survival in the current market makes both recruitment and retention efforts critical. One primary concern is an aging workforce. The American Nursing Association projects that 65% of current nurses will retire within this decade and predicts that the supply will no longer meet the demand by the year 2010.1 In fact, by 2020, the health care industry will need 1.7 million nurses—yet only 600,000 will be available.1 The key for success is retention of your current staff. 相似文献
30.
Botulinum Toxin A in the Treatment of Chromhidrosis 总被引:1,自引:0,他引:1
Wu Jessie M. Mamelak Adam J. MD † Nussbaum Rachel MD † McElgunn Patrick S. J. MD MBA † 《Dermatologic surgery》2005,31(8):963-965
Background. Chromhidrosis is an uncommon disorder characterized by secretion of colored sweat by apocrine glands, typically localized to the face or axilla. The current treatments available for chromhidrosis are time consuming and frequently ineffective.
Objective. Our purpose is to demonstrate a novel approach to the treatment of apocrine chromhidrosis.
Methods. We report a case of apocrine chromhidrosis successfully treated with botulinum toxin A (BTX-A; Botox).
Results. BTX-A therapy successfully controlled facial chromhidrosis, and the effects were visible at 19 weeks post-treatment. The therapeutic benefits may be attributed to its inhibitory effects on cholinergic stimulation, adrenergic stimulation, and substance P release, although further studies are necessary to elucidate the precise mechanism of action.
Conclusion. This report demonstrates a new therapeutic approach to patients suffering from chromhidrosis. 相似文献
Objective. Our purpose is to demonstrate a novel approach to the treatment of apocrine chromhidrosis.
Methods. We report a case of apocrine chromhidrosis successfully treated with botulinum toxin A (BTX-A; Botox).
Results. BTX-A therapy successfully controlled facial chromhidrosis, and the effects were visible at 19 weeks post-treatment. The therapeutic benefits may be attributed to its inhibitory effects on cholinergic stimulation, adrenergic stimulation, and substance P release, although further studies are necessary to elucidate the precise mechanism of action.
Conclusion. This report demonstrates a new therapeutic approach to patients suffering from chromhidrosis. 相似文献